A Canadian defence win, a regulatory catalyst for digital health, and a sobering revenue update from a first-year AI group shaped the small-cap tech tape on Friday. Pennant International (AIM:PEN) secured the largest contract in the day's news, while MedPal AI (AIM:MPAL) rode a UK regulatory development and Pri0r1ty Intelligence Group (AIM:PR1) faced a sharp sell-off after disclosing its early revenue position.
Pennant lands C$35m eleven-year Royal Canadian Navy deal
Pennant International Group (AIM:PEN) secured a C$35m framework contract to support the Royal Canadian Navy's software suite, with the agreement running for eleven years and underpinning recurring revenue in the company's higher-margin software and services division. The contract represents a significant addition to Pennant's defence backlog and reinforces its position as a provider of mission-critical training and support systems to NATO-aligned navies. Shares in Pennant rose 10.6% to 26.0p on the announcement.
UK approval of oral semaglutide opens new market for MedPal
MedPal AI (AIM:MPAL) told investors that the UK's approval of the first oral GLP-1 weight-loss pill represents a material commercial opportunity for its platform, removing the barrier of self-injection and expanding the population of patients likely to seek treatment. The company pointed to early evidence from the US, where oral semaglutide has already broadened uptake, as a template for how the private UK market could develop. MedPal's shares surged 33.9% to 4.15p following the update.
Pri0r1ty Intelligence books £0.4m revenue in maiden trading year
Pri0r1ty Intelligence Group (AIM:PR1) disclosed £0.4m in contracted revenue eight months into its first full financial year, having signed clients including Aston Villa, EuroLeague Basketball and World Aquatics for its AI and marketing services offering. While the client roster carries recognisable names, the revenue quantum fell short of market expectations and the stock fell 48.5% to 0.875p, a severe de-rating for a group still in its commercial infancy. The update underscores the execution risk facing early-stage AIM-listed AI businesses as investors apply tighter scrutiny to revenue conversion.
